View Menu Hide Menu

Recent publications and conference presentations from VHsquared include:

The British Society of Gastroenterology Annual Meeting 2018, June 4-7, Liverpool UK – presented as an Abstract of Distinction

V565, a Novel, Oral Anti-TNF Domain Antibody, Reduces Colonic Mucosal Inflammation in Patients with Ulcerative Colitis

 

 

 

11th Annual Proteins and Antibodies Congress, April 16-17 2018, London UK & 17th Annual Pep Talk, January 8-12 2018, San Diego, USA

V565 is a highly potent, orally-delivered, anti-TNFα VorabodyTM that is highly stable during intestinal transit in cynomolgus monkeys

 

 

 

V565, an intestinal protease-stabilised oral anti-TNFα VorabodyTM, inhibits inflammation in ulcerative colitis patients

 

 

 

March 21, 2018 – Preclinical research supporting use of oral anti-TNFα Vorabody V565 in IBD treatment published in Scientific Reports

First full account of V565 preclinical development available in open access journal

 

 

 

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease

 

 

 

13th Congress of ECCO, February 14-17 2018, Vienna, Austria

Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBD

 

 

 

2017 Antibody Engineering & Therapeutics meeting, December 10-14 2017, San Diego, USA

Predicting intestinal tract luminal concentrations after oral dosing of an anti-TNFα​ domain antibody engineered for intestinal protease resistance

 

 

 

PEGS Europe Protein and Antibody Engineering Summit, November 13-17 2017, Lisbon, Portugal

Gastrointestinal Stability and Tissue Penetration of V565: a Novel Orally Administered Anti-TNFα Vorabody

 

 

 

Orally delivery of a novel engineered anti-TNFα domain antibody (Vorabody) for the treatment of Intestinal Bowel Disease

 

 

 

25th United European Gastroenterology Week, Oct 28- Nov 1 2017, Barcelona, Spain

A Protease-resistant Oral Domain Antibody to TNFα Delivers High Concentrations of Active Compound in Ileal Fluid of Subjects with an Ileostomy

 

 

Oral presentation – V565, A Novel Oral Domain Antibody to TNF, Reduces Colonic Mucosal Inflammation after 7 Days Oral Dosing to Patients with Ulcerative Colitis. (Contact us here for more information.)

Oral presentation – A Novel Oral Domain Antibody to Tumour Necrosis Factor (TNF), Engineered to be Stable to Intestinal Proteases, Results in High Concentrations of Active Compound Detected in Faeces of Crohn’s Patients After Oral Dosing. (You can read the abstract, OP272 here, or contact us here for more information.)


18th International Congress of Mucosal Immunology, July 19-22 2017, Washington DC, USA

Preclinical assessment of a novel anti-TNFα Vorabody™ as an oral therapy for Crohn’s Disease

 

 


Global Conference on Pharmaceutics and Drug Delivery Systems, June 29 – July 1 2017, Valencia Spain

Oral delivery of a novel domain antibody (Vorabody™) for the treatment of Crohn’s Disease

 

 

10th Annual Proteins and Antibodies Congress, April 24-25 2017, London UK

Gastrointestinal Stability and Tissue Penetration of V565:A Novel Orally Administered Anti-TNFα Vorabody™